Compare IMMP & XYF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMMP | XYF |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | Australia | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.9M | 260.6M |
| IPO Year | N/A | 2018 |
| Metric | IMMP | XYF |
|---|---|---|
| Price | $2.90 | $5.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 213.5K |
| Earning Date | 02-22-2026 | 11-20-2025 |
| Dividend Yield | N/A | ★ 9.76% |
| EPS Growth | N/A | ★ 49.84 |
| EPS | N/A | ★ 5.72 |
| Revenue | $3,306,742.00 | ★ $1,106,908,607.00 |
| Revenue This Year | $292.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.00 |
| Revenue Growth | 31.28 | ★ 47.14 |
| 52 Week Low | $1.32 | $5.44 |
| 52 Week High | $3.53 | $20.36 |
| Indicator | IMMP | XYF |
|---|---|---|
| Relative Strength Index (RSI) | 65.98 | 25.96 |
| Support Level | $2.52 | $5.44 |
| Resistance Level | $3.32 | $6.74 |
| Average True Range (ATR) | 0.22 | 0.34 |
| MACD | 0.04 | 0.10 |
| Stochastic Oscillator | 62.18 | 23.37 |
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.